@siren4 the company presented shareholders with market sensitive news indicating that an application for orphan drug designation to the FDA would be made in Calendar Year 2018.
If this doesn’t happen and management have intentionally or unintentionally misled shareholders without an explanation; I would hope the ASX will ask for a pause in trading to clarify the information.
fair enough?
in saying that, today the company publicised via evolis australia a significant virtual trophy being rated as a must have product in 2018
plenty of good news around if your prepared to go searching for it.
no doubting the company has huge potential, we are staunch believers or we wouldn’t be sitting here; in saying that, the long jevity of this investment and failure to date to deliver for shareholders has become a much personal issue for all shareholders
anyone trying to hoodwink shareholders might be waking up with a horses head laying beside them
Try and keep the faith crew; for another week at the very least!
